SEOUL, November 16 (AJP) — The U.S. Food and Drug Administration (FDA) has rejected ivonescimab, a lung cancer drug invented by China’s Akeso, setting back a medicine that had become the leading example of China’s rise as a source of new drugs. Summit Therapeutics, the Miami-based company that bought the drug’s U.S. rights from Hong Kong-listed Akeso, disclosed the decision on Sunday. The agency found that ivonescimab slowed the cancer’s progression in a global late-stage trial but did not show a statistically significant survival benefit, and extra analyses Summit filed afterward did not change regulators’ minds. The rejection applies only to a narrow group of patients with advanced lung cancer whose earlier targeted therapy had stopped working. Attention now turns to a trial pitting the drug against Merck’s Keytruda in patients who have not yet been treated, which is expected to report results by year-end. Co-chief executive Bob Duggan said “nothing changes” in Summit’s belief in the drug. AJP Takeaways The U.S. Food and Drug Administration rejected ivonescimab, invented by China’s Akeso, because it did not show a statistically significant survival benefit, even though it slowed cancer progression. The decision covers only a narrow group of advanced lung cancer patients whose earlier targeted therapy had stopped working. Attention now turns to a trial against Merck’s Keytruda in patients who have not yet been treated. Tags: Summit Therapeutics, Akeso, U.S. Food and Drug Administration, FDA, ivonescimab, Keytruda, Merck, Bob Duggan, lung cancer, China biotech
